OptiBiotix Health
plc
("OptiBiotix" or the "Company")
Directorate
change
OptiBiotix Health plc (AIM: OPTI), a life sciences
business developing compounds to tackle obesity, high cholesterol,
diabetes and skincare, announces that, further to the announcement on 23 October
2024, David Blain has been appointed to the Board as Finance
Director and Company Secretary effective from 7 January
2025.
David is a member of the Institute
of Chartered Accountants in England & Wales and has extensive
financial, commercial and Board experience in a number of private
and public companies, including Iksuda Therapeutics Ltd, Applied
Graphene Materials plc, Nanoco Group plc and Inspired Capital plc
(formerly Renovo Group plc). Mr Blain is currently Financial
Director (non-board position) at Iksuda Therapeutics
Ltd.
David's appointment to this
part-time role will see him work closely with the OptiBiotix team
to support the focus on driving each
business unit and the Group to profitability.
Pursuant to Rule 17 and Schedule
2(g) of the AIM Rules for Companies, the following information is
disclosed in respect of David Jonathan Blain (aged 63):
|
Current Directorships
|
Previous Directorships held in the past five
years
|
|
Blain Associates Limited
|
Applied Graphene Materials Limited
(formerly Applied Graphene Materials plc)
|
|
|
Applied Graphene Materials
LLC
|
|
|
Applied Graphene Ventures
Limited
|
|
|
Universal Matter GBR Ltd (formerly
Applied Graphene Materials UK Limited)
|
David Blain does not hold any
ordinary shares, options or warrants over new ordinary shares in
the Company.
There is no further information
regarding David Blain required to be disclosed under the AIM
Rules.
Stephen O'Hara, CEO of OptiBiotix commented:
"We are pleased to confirm the appointment of David as Finance Director and Company
Secretary. The appointment reflects the Board's focus on managing
costs and building revenues to create profitable business units and
an international business with well-known global brands."
The Directors of the Company are
responsible for the release of this announcement.
For
further information, please contact:
|
OptiBiotix Health plc
|
www.optibiotix.com
|
|
Neil Davidson, Chairman
|
Contact via Walbrook
below
|
|
Stephen O'Hara, Chief
Executive
|
|
|
|
|
|
Cairn Financial Advisers LLP (NOMAD)
|
Tel: 020
7213 0880
|
|
Liam Murray / Jo Turner / Ludovico
Lazzaretti
|
|
|
|
|
|
Peterhouse Capital Limited (Joint Broker)
|
Tel: 020
7220 9797
|
|
Duncan Vasey / Lucy
Williams
|
|
|
Walbrook PR Ltd
|
Mob: 07876
741 001
|
|
Anna Dunphy
|
|
|
|
| |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI),
which was formed in March 2012, brings science to the development
of compounds which modify the human microbiome - the collective
genome of the microbes in the body - in order to prevent and manage
human disease and promote wellness.
OptiBiotix has an extensive R&D
programme working with leading academics in the development of
microbial strains, compounds, and formulations which are used as
active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements
with OptiBiotix to incorporate their human microbiome modulators
into a wide range of food products and drinks.
OptiBiotix is also developing its
own range of consumer supplements and health products. The
Company's current areas of focus include obesity, cardiovascular
health, and diabetes.